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Autoimmune pancreatitis (AIP) is a benign disorder and a 
unique form of chronic pancreatitis with several character-
istic features. A cystic formation that mimics a pseudocyst 
is a rare ﬁ  nding. There have been a few reports of AIP com-
plicated by pancreatic cysts. We present a case of AIP with 
multiple pseudocysts and obstructive jaundice caused by 
IgG4-associated cholangitis. We initially missed the diagnosis 
due to the pseudocyst. Based on the computed tomography 
images, laboratory ﬁ  ndings and the therapeutic response to 
steroids, the case was diagnosed as AIP with pseudocysts 
and associated cholangiopathy. (Gut Liver 2012;6:132-135)
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INTRODUCTION
It is well known that causes of chronic pancreatitis include 
alcohol, genetic or metabolic disorders, pancreato-biliary abnor-
malities and drugs. Since Sarles et al.
1 reported chronic pancre-
atitis associated with hypergammaglobulinemia and lymphocyt-
ic infiltration with fibrosis of the pancreas in 1961, autoimmune 
mechanisms have come to the forefront as additional important 
causes of chronic pancreatitis.
Autoimmune pancreatitis (AIP) is a benign disease and a 
unique form of chronic pancreatitis characterized by the pres-
ence of auto-antibodies, high serum IgG4 level, diffuse pancre-
atic swelling, irregular narrowing of the main pancreatic duct 
and stenosis of the intrahepatic and extrahepatic bile ducts. 
Lymphoplasmocytic infiltration and fibrosis of the pancreas are 
typical histologic findings of AIP.
2 IgG4-associated cholangi-
tis, described below, is commonly manifested with AIP and its 
diagnostic criteria include: stricture of intrahepatic, proximal 
extrahepatic or intrapancreatic ducts; clinical imaging findings 
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of AIP; and elevated serum IgG4.
3
We now report a case of AIP with accompanying multiple 
pseudocysts and IgG4-associated cholangitis. We think that this 
is a unique case of AIP, with clinical characteristics and course 
very similar to those of idiopathic chronic pancreatitis as well as 
other cases of AIP associated pseudocyst.
4
CASE REPORT 
A 47-year-old male patient was referred to our hospital with 
pancreatic swelling, multiple cystic lesions of the pancreas on 
ultrasonography (USG) and a history of upper abdominal pain. 
Intermittent upper abdominal discomfort and dyspepsia had 
been developing for 1 year, but there were no specific abnor-
mal findings on esophagogastroduodenoscopy and USG. Four 
months earlier, subsequent to an episode of abdominal pain, 
abdominal computed tomography (CT) had revealed pancreatic 
pseudocyst. Post-referral abdominal CT showed diffuse pancre-
atic swelling and variably sized multiple pseudocysts without 
pancreatic parenchymal calcification (Fig. 1). For follow-up 
periods in outpatient clinic, he had complained intermittent 
vague abdominal discomfort without a history of aggravation 
of abdominal symptoms. A yellowish facial color developed and 
became more severe, and the patient was admitted for evaluation. 
He had been treated for pulmonary tuberculosis 20 years previ-
ously, but there was no other significant past medical or family 
history, including cholelithiasis. He had a 15 pack year smoking 
history but had no history of excessive alcohol consumption. 
In physical examination and systemic review, blood pressure, 
pulse rate, body temperature, and respiratory rate were stable 
and body mass index was 19.6 kg/m
2. The abdomen was soft 
and there was no palpable mass. There were no abnormal physi-
cal findings except systemic jaundice. Laboratory data were as 
follows (values in parentheses indicate normal range): white Sohn JW, et al: A Case of Autoimmune Pancreatitis Manifested by a Pseudocyst and IgG4-Associated Cholangitis  133
blood cell (WBC) count 6,440/mm
3 (4,800 to 10,800/mm
3); he-
moglobin 11.9 g/dL (13 to 18 g/dL); platelet count 266,000/mm
3 
(130,000 to 400,000/mm
3); aspartate aminotransferase (AST) 
317 IU/L (0 to 37 IU/L); alanine aminotransferase (ALT) 484 IU/
L (0 to 41 IU/L); alkaline phosphatase (ALP) 517 IU/L (35 to 129 
IU/L); gammaglutamyl transpeptidase (GGT) 489 IU/L (8 to 61 
IU/L); total bilirubin 12.01 mg/dL (0.01 to 1.1 mg/dL); direct bil-
irubin 10.48 mg/dL (0.01 to 0.3 mg/dL); amylase 82 IU/L (28 to 
110 IU/L), lipase 675 IU/L (23 to 300 IU/L); fasting blood sugar 
155 mg/dL (7 to 100 mg/dL); hemoglobin A1c 5.5% (4.0% to 6.5 
%); CEA 5.36 ng/mL (0 to 4.3 ng/mL); CA 19-9 111.1 U/mL (0 
to 37 U/mL).
Initial dynamic CT demonstrated diffuse pancreatic swelling 
and multiple pseudocysts, new intrahepatic and extrahepatic 
bile duct dilatation, and irregular wall thickening and a 2 cm 
length stenosis of the proximal common bile duct (CBD) (Fig. 
2). Endoscopic retrograde cholangiopancreatography (ERCP) 
showed stenosis of the proximal CBD without demonstrating 
malignancy (Fig. 2).
We made the provisional diagnosis of chronic pancreatitis 
with biliary stricture and placed a biliary stent into stenotic bile 
duct. During outpatient follow-up, the jaundice resolved and 
tumor marker and biochemical laboratory data normalized, but 
vague abdominal discomfort, nausea and intermittent vomiting 
persisted. While follow-up abdominal dynamic CT revealed no 
bile duct dilatation and similar pancreato-biliary abnormalities 
to those on the initial CT, enhanced-phase CT showed diffuse 
pancreatic swelling without focal enhancing mass lesion at pan-
creas and low attenuation of peripancreatic area which findings 
were compatible with AIP.
5
We performed additional laboratory tests for autoimmune dis-
orders as follows (values in parentheses indicate normal range): 
antinuclear antibody was negative; antimitochondrial antibody 
(AMA) was negative; rheumatoid factor was negative; IgG 1,845 
mg/dL (700 to 1,600 mg/dL); IgA 201 mg/dL (70 to 400 mg/dL); 
IgM 55 mg/dL (40 to 230 mg/dL); IgG subtype IV 2.28 g/L (0.06 
to 1.21 g/L). Based on the findings of the two imaging criteria 
and a serologic criterion of the Asian Diagnostic criteria for AIP, 
we diagnosed AIP.
4,6
Outpatient oral prednisolone therapy was started at a dose 
of 30 mg/day. After 3 months, the symptoms had completely 
resolved without any complications. Abdominal dynamic CT 
showed partial resolution of the pseudocysts, in size and num-
bers, and improvement of the diffuse pancreatic swelling (Fig. 
3). ERCP revealed normal intra- and extrahepatic bile ducts, in-
cluding the CBD and main pancreatic duct, and the plastic stent 
previously placed at the distal CBD was removed. Small stones 
were detected in the CBD and removed using basket. Labora-
tory data concerning liver function, and levels of pancreatic 
enzymes and IgG4 were normalized or improving (AST, 18 IU/L; 
Fig. 1. The computed tomography 
findings on the first visit of the pa-
tient to our hospital in May 2008. 
There is a diffuse enlargement of the 
pancreas with multiple pseudocysts 
without parenchymal calcification.134  Gut and Liver, Vol. 6, No. 1, January 2012
ALT, 13 IU/L; ALP, 55 IU/L; GGT, 13.6 IU/L; total bilirubin, 0.74 
mg/dL; direct bilirubin, 0.06 mg/dL; amylase, 30 IU/L, lipase, 10 
IU/L; CEA, 2.92 ng/mL; CA 19-9, 5.4 U/mL; IgG4, 1.63 g/L). The 
dose of oral prednisolone was subsequently tapered in phases to 
10 mg as the patient’s vague abdominal discomfort, nausea and 
vomiting resolved. At present, the patient is asymptomatic on 
10 mg oral prednisolone per day.
DISCUSSION
In 1995, Yoshida et al.
7 summarized the characteristics of AIP 
as follows: 1) Increase of serum gamma globulin or IgG levels; 2) 
Presence of auto-antibodies; 3) Diffuse enlargement of pancre-
as; 4) Irregular narrowing of the main pancreatic duct on ERCP; 
5) Fibrotic changes and lymphocyte infiltration of the pancreas 
on histology; 6) Asymptomatic or mild symptoms, usually no 
history of acute pancreatitis; 7) Stenosis of the CBD in the pan-
creas, with dilatation of upstream bile duct and liver dysfunc-
Fig. 2. Computed tomography (CT) 
(A) and endoscopic retrograde chol-
angiopancreatography (ERCP) (B) 
findings at the time of admission 
for the evaluation of jaundice in 
July 2008. CT shows diffuse intra-
hepatic duct dilatation, focal luminal 
wall thickening and a narrowing 
lesion at the proximal common bile 
duct (CBD). ERCP demonstrates the 
stenosis of the proximal CBD with 
upstream dilation.
Fig. 3. The computed tomography 
(CT) and endoscopic retrograde chol-
angiopancreatography (ERCP) find-
ings after corticosteroid treatment 
for 3 months. (A) CT reveals an im-
provement in parenchymal swelling 
and the size and numbers of pseu-
docysts. (B) ERCP shows a complete 
resolution of the luminal narrowing 
and stricture of the proximal com-
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tion; 8) No pancreatic calcification; 9) No pancreatic cyst; 10) 
Frequently associated with other autoimmune disorders; 11) 
Good response to steroid treatment.
There have only been a few reports of AIP complicated with 
pancreatic cyst and such cysts are rare, probably due to the ab-
sence of severe tissue necrosis and/or lack of stasis of the pan-
creatic juice in this condition.
In this case, when the patient visited our hospital initially, 
he had a history of an acute attack of pancreatitis and diffuse 
enlargement of the pancreas with multiple pseudocysts on im-
aging. Chronic pancreatitis or pancreatic cystic neoplasm were 
therefore deemed more likely than AIP. Also, pseudocysts located 
in the pancreatic head are particularly suggestive of pancreatic 
cancer, and we therefore performed ERCP to exclude pancreatic 
malignancy. Responsiveness of AIP to corticosteroid treatment 
corresponds to elevation of IgG/IgG4 or else the presence of other 
auto-antibodies such as ANA.
8 In addition, pseudocyst associated 
with AIP might represent a highly active inflammatory process, 
and these lesions have been shown to predict responsiveness to 
corticosteroid treatment if associated with AIP.
4
Though we were unable to determine the exact mechanism of 
the pathogenesis of the cyst in the present patient, the absence 
of both severe acute episodes of pancreatitis and a marked el-
evation of serum pancreatic enzymes prior to cyst formation 
suggests that severe tissue necrosis did not contribute to the 
pathogenesis. Cyst formation in AIP may be associated with a 
highly active state of the inflammatory process, as we found a 
high serum IgG4 concentration that closely correlated with the 
active state of this disease. Pseudocyst activity and progression 
is known to be associated with stenosis of the pancreatic duct. 
Steroids are thought to induce pseudocyst regression through 
inhibition of inflammation of the pancreatic duct, thus reducing 
the stenosis and improving the drainage of pancreatic juice.
Corticosteroid treatment is clinically, radiologically, and 
serologically effective and has become accepted as a standard 
treatment for AIP. There have been some studies on the short-
term effectiveness of corticosteroid treatment in AIP, and, more 
recently, on the long-term prognosis for patients with AIP, in-
cluding those receiving corticosteroid treatment.
9 It is difficult 
for all patients with AIP to be treated with corticosteroid, and 
there is currently no consensus on when to initiate corticoste-
roid treatment in patients with AIP. Hirano et al.
10 reported that 
a growing pancreatic pseudocyst developed in an AIP patient 
who did not receive corticosteroid treatment, while Nakazawa et 
al.
11 reported the spontaneous disappearance of a pancreatic cyst 
in an AIP patient without corticosteroid treatment. Kawakami 
et al.
12 suggested that, in AIP patients, corticosteroid treatment 
should be started immediately after pseudocyst appearance be-
cause of the possibility of pseudocyst regression with treatment.
The risk of adverse effects of corticosteroid treatment (such as 
susceptibility to infection, impaired glucose tolerance and peptic 
ulcer) should also be taken into consideration. 
The indications for corticosteroid therapy in AIP patients 
have included bile duct stenosis and various other symptoms 
and clinical findings.
10 In this case, we started corticosteroid 
treatment after diagnosis of IgG4-associated cholangitis, which 
caused obstructive jaundice due to bile duct stenosis, and pseu-
docysts. After corticosteroid treatment, there were improvements 
in clinical symptoms, such as reduced abdominal discomfort 
and nausea. Radiologic regression of the diffuse pancreatic 
swelling, bile duct stenosis and pseudocysts was also seen and 
the patient has recovered well with no complications. More 
studies are required regarding the long-term prognosis and ap-
propriate duration of corticosteroid treatment for AIP.
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